Tesamorelin · source year
3 selected, source-linked Tesamorelin records carrying a 2020 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
3 selected records.
3 represented types.
3 distinct public records.
Cited chronology
Regulatory
DailyMed lists Structured Product Labeling version 2 for the reviewed Tesamorelin label family with a published date of 2020-04-22. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 31237318 at 2026-07-30T20:30:10.504Z. PubMed recorded a metadata revision date of 2020-04-07 and an Entrez history date of 2019-06-26. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02196831 at 2026-07-30T20:33:20.623Z. Its registry update date was 2020-01-27, and PeptideScanner's reviewed identity mapping was tesamorelin.
Source: ClinicalTrials.gov ↗